Krystal Biotech (KRYS) said Monday its Vyjuvek treatment for dystrophic epidermolysis bullosa received marketing authorization from the European Commission.
The decision allows the marketing of the treatment in all EU member states, as well as Iceland, Norway and Liechtenstein, with availability subject to multiple factors, the company said.
Krystal said it is planning for the treatment's first European launch in Germany in mid-2025.
Shares were up 2% in early trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。